Почетна › Рак јетре (хепатоцелуларни карцином) › Тексас
Kliničke studije za Рак јетре (хепатоцелуларни карцином) u državi Тексас
48 studija za Рак јетре (хепатоцелуларни карцином) traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- Mays Cancer Center, UT Health San Antonio, San Antonio
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06698250High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- M D Anderson Cancer Center, Houston
Тражи се учесник
Узраст 19 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05053555Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04982653A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 16 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07197554Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- St. David's Medical Center, Austin
Тражи се учесникОпсервациона студија
Узраст 22 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT06486454DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA13-0, Anderson
- USA12-0, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06953089A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Dallas
- Clinical Trial Site, Houston
- Clinical Trial Site, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06600321A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Harold C. Simmons Comprehensive Cancer Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- DHR Health Institute for Research and Development, McAllen
- и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT05440708A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 135, Austin
- Research Site 120, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06582017First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06795022Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- MD Anderson Cancer Center /ID# 255131, Houston
- Univ Texas HSC San Antonio /ID# 257708, San Antonio
- South Texas Accelerated Research Therapeutics /ID# 260404, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07749586Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Amarillo
- Research Site, Austin
- Research Site, Houston
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06921785FOG-001 in Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT05919264Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
- M D Anderson Cancer Center, Houston
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Сви узрасти · Оба пола · Ажурирано 6. 10. 2026. · NCT05143619A Study of ZW251 in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07164313Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- и још 2
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06726161National Liver Cancer Screening Trial
- UT Southwestern Medical Center and Parkland Hospital, Dallas
- Baylor College of Medicine, Houston
Тражи се учесникФаза 4
Узраст од 18 до 85 · Оба пола · Ажурирано 25. 9. 2026. · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06427941GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 9. 2026. · NCT04864054THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесникРана фаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT07446257Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT07689175IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 8. 2026. · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
Тражи се учесникФаза 2
Узраст 8 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05503797A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- и још 8
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT05208762Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 7. 2026. · NCT05092373Multi-analyte Blood Test Clinical Trial
- South Texas Research Institute, Edinburg
- Texas Gastro Research, El Paso
- Impact Research Institute, Waco
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 10. 7. 2026. · NCT05199259CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 2. 7. 2026. · NCT06184152Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Тражи се учесник
Узраст од 18 до 75 · Оба пола · Ажурирано 17. 6. 2026. · NCT05486572A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT07116486A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 4. 2026. · NCT06362369Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 4. 2026. · NCT05733598Evaluation of Resection Techniques for Pancreatic Tumors
- Methodist Dallas Medical Center, Dallas
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 20. 3. 2026. · NCT05128890Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Oncology Consultants, Houston
Тражи се учесникФаза 1
Узраст од 18 до 65 · Оба пола · Ажурирано 16. 3. 2026. · NCT07176650Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 2. 2026. · NCT06789848Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.